Compare Royalty Pharma plc Class A Ordinary Shares (RPRX) vs Thomson Reuters Corp (TRI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Royalty Pharma plc Class A Ordinary Shares vs Thomson Reuters Corp — how do they compare? Royalty Pharma plc Class A Ordinary Shares trades at $56.69 (market cap $25.27B), while Thomson Reuters Corp trades at $101.64 (market cap $43.89B). The key difference: Thomson Reuters Corp is the larger of the two by market cap, and Thomson Reuters Corp pays the higher dividend (2.58%). Which is the better fit depends on your goals — on Pluang, investors hold Royalty Pharma plc Class A Ordinary Shares for 0 Days and Thomson Reuters Corp for 63 Days on average.
| RPRX | TRI | |
|---|---|---|
Market Cap | $25.27B | $43.89B |
Volume | 3,671,183 | 1,648,199 |
Sector | Health | Industrials |
52-Week High | $63.96 | $163.45 |
52-Week Low | $35.44 | $76.55 |
Typical Hold Time | 0 Days | 63 Days |
Enterprise Value | $32.50B | $46.51B |
Dividend Yield | 1.66% | 2.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Thomson Reuters (TRI) trades at $101.52, up 2.26% today, with bullish technical signals and strong analyst support. The company shows solid fundamentals with 10% organic growth in core businesses and a 21.22% net income margin. Recent strategic moves include divesting its printing unit and launching a proprietary AI model, positioning TRI for tech-focused growth. Cash flow trends show operational strength despite recent negative net cash flow due to strategic investments.
TRI presents a compelling investment case with analyst consensus target of $133.25 (31% upside), supported by recurring revenue growth and AI expansion. Risks include cybersecurity incidents and execution challenges in tech transformation. The stock's current valuation at 26.75 P/E appears reasonable given growth prospects, making it attractive for long-term investors seeking exposure to content and technology services.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma acquires interests in royalties from biopharmaceutical products. Its model gives it exposure to medicines developed and sold by other life sciences companies.
Read more on RPRX →About Thomson Reuters Corp
Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →
